Amniotics AB (publ) (AMNI.ST)

0.0039 +0.0001 (+2.63%) At close: 12:25PM CEST

Amniotics AB (publ)

ScheelevAegen 2
Building 406
Lund 22381
Sweden
46 0 72 32 78 520
https://www.amniotics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 6

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Marcus Larsson Ph.D.	Founding Member, CEO & Director	N/A	N/A	1973
Mr. Gerton Jonsson	Chief Financial Officer	N/A	N/A	1971
Mr. Jan Talts	Chief Operating Officer	N/A	N/A	1965
Ms. Sidonie Karlsson	Head of Manufacturing	N/A	N/A	1975

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.

Description

Amniotics AB (publ) develops stem cell-based therapeutics to treat severe life-threatening diseases. The company's lead drug candidate is PulmoStem for the treatment of lung disease. It also develops CogniStem for the treatment of CNS indications; NephroStem for the treatment of kidney-specific indications; CutiStem for the treatment of dermatological indications; and AMNI-NK003. The company offers contract development and contract manufacturing services for advanced therapy medicinal products to the pharmaceutical industries, universities, and hospitals. Amniotics AB (publ) was incorporated in 2015 and is based in Lund, Sweden.

Corporate governance

Amniotics AB (publ)’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.